Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan
Open accessThe DOI matches its Crossref record; 86 of the 89 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Polycystic ovary syndrome (PCOS) is of clinical and public health importance as it is very common, affecting up to one in five women of reproductive age. It has significant and diverse clinical implications including reproductive (infertility, hyperandrogenism, hirsutism), metabolic (insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, adverse cardiovascular risk profiles) and psychological features (increased anxiety, depression and worsened quality of life). Polycystic ovary syndrome is a heterogeneous condition and, as such, clinical and research agendas are broad and involve many disciplines. The phenotype varies widely depending on life stage, genotype, ethnicity and environmental factors including lifestyle and bodyweight. Importantly, PCOS has unique interactions with the ever increasing obesity prevalence worldwide as obesity-induced insulin resistance significantly exacerbates all the features of PCOS. Furthermore, it has clinical implications across the lifespan and is relevant to related family members with an increased risk for metabolic conditions reported in first-degree relatives. Therapy should focus on both the short and long-term reproductive, metabolic and psychological features. Given the aetiological role of insulin resistance and the impact of obesity on both hyperinsulinaemia and hyperandrogenism, multidisciplinary lifestyle improvement aimed at normalising insulin resistance, improving androgen status and aiding weight management is recognised as a crucial initial treatment strategy. Modest weight loss of 5% to 10% of initial body weight has been demonstrated to improve many of the features of PCOS. Management should focus on support, education, addressing psychological factors and strongly emphasising healthy lifestyle with targeted medical therapy as required. Monitoring and management of long-term metabolic complications is also an important part of routine clinical care. Comprehensive evidence-based guidelines are needed to aid early diagnosis, appropriate investigation, regular screening and treatment of this common condition. Whilst reproductive features of PCOS are well recognised and are covered here, this review focuses primarily on the less appreciated cardiometabolic and psychological features of PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schema of aetiology and clinical features including reproductive, metabolic and psychosocial features of polycystic ovary syndrome (PCOS). Reproduced with permission from [82].](https://figures.cochat.ai/paper-figures/ba6dd207954c4ccea0560e719bee27b2/polycystic-ovary-syndrome-a-complex-condition-with-psychological-reproductive-figure-1.jpg)
![Figure 2 Summary of a targeted approach to therapy in polycystic ovary syndrome (PCOS). Reproduced with permission from [82].](https://figures.cochat.ai/paper-figures/aea8c8d83d0748a1af73bd3d99542ce7/polycystic-ovary-syndrome-a-complex-condition-with-psychological-reproductive-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PCOS prevalence is between 10% and 13% as confirmed in the guideline process. 1,2”
From Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PCOS prevalence is between 10% to 13% as confirmed in the guideline process (1, 2).”
From Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting reproductive-aged women, with impacts across the lifespan from adolescence to post menopause.”
From Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“PCOS aetiology is complex”
From Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“clinical presentation is heterogeneous with reproductive, metabolic, and psychological features (1, 2).”
From Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023) · cites this paper as [1]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427 · cited 4×
“Some studies support an increased risk of CVD in PCOS [18], but these findings are not universal [61] and further research is needed.”
InfluentialRetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 4×
“• Metformin* reduces the risk of diabetes by approximately 50% in high-risk groups [49].”
Influential(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 2×
“Proc Natl Acad Sci USA 2006, 103:7030-7035.”
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 2×
“Interestingly, there is a paradoxical expression of insulin resistance in PCOS whereby insulin-stimulated androgen production persists while its role in glucose metabolism is impaired [42].”
Men at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 8×
“National Institutes of Health criteria consensus statement [83] European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine consensus statement [20] Androgen Excess Society position statement [ 21 ]”
InfluentialAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132 · cited 1×
“Among those with amenorrhoea, only 40% will be diagnosed with PCOS as hypothalamic dysfunction is a more common cause [ 31 ].”
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 2×
“Lean women with PCOS often but not always [13] have abnormalities of insulin secretion and action compared to weight-matched control subjects [41].”
March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I. W., Norman, R. J., & Davies, M. J. (2010) · Human Reproduction · doi:10.1093/humrep/dep399 · Cited by 1,799 · cited 4×
“8%) in the first community-based prevalence study based on current Rotterdam diagnostic criteria [5].”
Influential
Research works printed but not linked: 4
- Barr ELM Magliano DJ Zimmet PZ Polkinghorne KR Atkins RC Dunstan DW Murray SG Shaw JE AusDiab 2005: The Australian Diabetes, Obesity and Lifestyle Study 2006 Melbourne, Australia: International Diabetes Institute
- Dunstan D Zimmet P Welborne T Sicree RTA Atkins R Cameron A Shaw J Chadaban S Diabetes and associated disorders in Australia 2000 - the accelerating epidemic Australian Diabetes, Obesity and Lifestyle Report 2001 Melbourne, Australia: The International Diabetes Institute
- NHaMRC Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults 2003 Canberra, Australia: Australian Government Publishing Service
- Zawadzki J Dunaif A Dunaif A, Givens J, Haseltine F, Marrian G Diagnostic criteria for polycystic ovary syndrome: towards a rational approach Polycystic Ovary Syndrome Current Issues in Endocrinology and Metabolism 1992 Boston, MA: Blackwell Scientific 377 384
Cited by
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Self-citationTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., International PCOS Network, Andersen, M., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey256 · Cited by 1,593
Self-citationState-of-the-science of endocrine disrupting chemicals, 2012
Bergman, Å., Heindel, J., Jobling, S., Kidd, K., & Zoeller, R. T. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.03.020 · Cited by 1,388
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.004 · Cited by 1,325
Self-citationEpidemiology, diagnosis, and management of polycystic ovary syndrome
Sirmans, S., & Pate, K. (2013) · Clinical Epidemiology · doi:10.2147/clep.s37559 · Cited by 1,302
“Because a dominant follicle does not develop, ovulation does not ensue.(14,15) In addition,”
Metadata
- Authors
- Teede, H., Deeks, A., & Moran, L.
- Affiliations
- Jean Hailes (AU)
- Corresponding author
- Moran, L
- Venue
- BMC Medicine
- Published
- 2010-06-30
- Volume
- 8
- Issue
- 1
- Pages
- 41-41
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC2909929
- OpenAlex
- W2058294720
- Cited by
- 1,565
- References
- 89
- Citations by year
- 2026: 83 · 2025: 139 · 2024: 156 · 2023: 145 · 2022: 155 · 2021: 171 · 2020: 122 · 2019: 102 · 2018: 87 · 2017: 78 · 2016: 57 · 2015: 53 · 2014: 75 · 2013: 63 · 2012: 42
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, insulin resistance, obesity, hyperandrogenism, hirsutism, infertility, cardiometabolic risk, type 2 diabetes, cardiovascular risk, anxiety, depression, quality of life, weight loss, lifestyle intervention, first-degree relatives, metabolic complications, psychological manifestations
- MeSH terms
- Anxiety, Cardiovascular Diseases, Depression, Diabetes Mellitus, Female, Hirsutism, Humans, Infertility, Ovary, Polycystic Ovary Syndrome, Quality of Life, Reproduction, Hyperandrogenism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. https://app.cochat.ai/papers/10.1186/1741-7015-8-41
- The paper
- Teede, H., Deeks, A., & Moran, L. (2010). Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine. https://doi.org/10.1186/1741-7015-8-41
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.